Literature DB >> 26504050

Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.

Hideo Matsumoto1, Hideo Okumura2, Haruaki Murakami2, Hisako Kubota2, Masaharu Higashida2, Atsushi Tsuruta2, Kaoru Tohyama3, Toshihiro Hirai2.   

Abstract

BACKGROUND/AIM: It is generally believed that the plasma concentration of 5-fluorouracil (5-FU) is constant when 5-FU is continually administered for chemotherapy. The aim of the present study was to verify whether this is true. PATIENTS AND METHODS: Nine patients with colorectal cancer were enrolled in this study. All patients received chemotherapy; four patients received FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) and five received FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin). 5-FU was administered continuously (2400 mg/m(2)) for 46 h. Serum was collected at 12 points after the start of administration. The concentration of 5-FU was evaluated using a new immunoassay method and gas chromatography-mass spectrometric (GC/MS) method.
RESULTS: The concentrations of 5-FU fluctuated dramatically over time, with greater than 3-fold changes in each individual, and the pattern was not constant.
CONCLUSION: Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area. A new individualized method for determining the 5-FU dosage should be developed. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  5-FU-based chemotherapy; Concentration of 5-FU; FOLFIRI; FOLFOX; My5-FU™ immunoassay

Mesh:

Substances:

Year:  2015        PMID: 26504050

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.

Authors:  Quanliang Yang; Yanzhi Bi; Xiaoqian Li; Qian Liu; Jian Ma; Chengliang Zhang; Jinlin Zhang; Guangzhao He
Journal:  Eur J Hosp Pharm       Date:  2019-03-16

Review 2.  Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.

Authors:  Nattawut Leelakanok; Sean Geary; Aliasger Salem
Journal:  J Pharm Sci       Date:  2017-10-16       Impact factor: 3.784

3.  Effect of Ketorolac on Pharmacokinetics and Pharmacodynamics of 5-Fluorouracil: In Vivo and In Vitro Study.

Authors:  Motahare Atefinezhad; Ahmadreza Moghadamnia; Seyed Parsa Eftekhar; Ali Akbar Moghadamnia; Sohrab Kazemi
Journal:  J Trop Med       Date:  2022-09-21

4.  Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.

Authors:  Xingqin Zhou; Yazhou Chang; Jing Qian; Chaoyan Shen; Jie Han; Hongyu Zhao; Renan Chang
Journal:  Med Sci Monit       Date:  2021-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.